the controlled substances board evaluated the implementation of the national cancer institute ( nci ) program in wisconsin that distributes delta 9-tetrahydrocannabinol ( delta 9-thc ) to cancer chemotherapy patients with nausea and vomiting refractory to conventional antiemetic drugs .
C0039663
delta
C0027497
nausea